Sep 03, 2014 at 11:43 | Source: Moneycontrol.com
On Monday, Mumbai-based generic drugmaker Cipla launched the aerosol copy of GlaxoSmithKlines anti-asthma inhaler Adviar in two small European markets Germany and Sweden but the move could potentially serve as a precursor to a crack at more lucrative markets such as the US and the UK.
Sep 02, 2014 at 15:51 | Source: Moneycontrol.com
IOL Chemicals & Pharmaceuticals Ltd has informed BSE that the 27th Annual General Meeting (AGM) of the Company will be held on September 30, 2014.
Sep 02, 2014 at 14:52 | Source: Moneycontrol.com
Jubilant Life Sciences Ltd has informed BSE that the Annual General Meeting (AGM) of the Company was held on September 02, 2014.
Sep 02, 2014 at 10:53 | Source: Moneycontrol.com
Brooks Laboratories Ltd has submitted to BSE a copy of proceedings of the 12th Annual General Meeting of the Company held on August 08, 2014.
Sep 02, 2014 at 10:22 | Source: Moneycontrol.com
Though analysts are impressed by its earlier- than-expected launch, most of them have not yet upgraded Cipla yet. Credit Suisse maintains a neutral rating on it stating base case is already priced in. According to the brokerage, Germany and Sweden are small markets but the launch signifies approval in the UK could be expected by FY15-end.
Aug 30, 2014 at 14:32 | Source: CNBC-TV18
Last week, GSK consumer healthcare re-launched it's flagship health drink Horlicks with a new logo, packaging and commercial. Pavni Mittal of Storyboard caught up with Jayant Singh to understand the changes made to the brand and how it would be marketed.
Aug 28, 2014 at 15:01 | Source: Moneycontrol.com
Aurobindo Pharma Ltd has informed BSE that the 27th Annual General Meeting (AGM) of the Company was held on August 27, 2014.
Aug 28, 2014 at 14:34 | Source: Moneycontrol.com
Piramal Phytocare Ltd has clarified on the news item appearing in a leading financial newspaper dated August 28, 2014.
Aug 28, 2014 at 12:49 | Source: Moneycontrol.com
Firstcall Research is bullish on Ajanta Pharma Ltd and has recommended buy rating on the stock with a target of Rs 1758 in its August 28, 2014 research report.
Aug 28, 2014 at 10:29 | Source: Moneycontrol.com
Sun Pharmaceutical Industries Ltd has informed BSE that the Company is in receipt of direction under Section 29(2) of the Competition Act, 2002 from CCI directing Sun Pharma to publish the details of the proposed combination within 10 working days from August 27, 2014 in Form IV contained in Schedule II to the Combination Regulations.